New Jersey Cannabis
Market Intelligence Report
New Jersey crossed $1.16 billion in certified 2025 cannabis sales — a record — while adult-use flower prices fell 23% year-over-year and medical enrollment dropped to 52,877 patients. With 300+ dispensaries now operational in all 21 counties and the license pipeline at 2,521 approved applications, NJ is rapidly maturing from a launch-phase market into a competitive pricing environment.
Key Decision Summary
With 84% of awarded licenses not yet operational and Q4 2025's dispensary count doubling in four months, the buildout and compliance services pipeline is the largest single B2B opportunity in NJ right now — especially Metrc-compatible POS, security, and fit-out contractors for operators in their final CRC inspection phase.
Flower prices fell 23.3% YoY in April 2026 with no structural floor in sight. New cultivators and craft growers entering the wholesale market will push prices lower before equilibrium. Operators banking on NJ's early-market premium pricing are already behind.
NJ is most compelling for vendors serving a high-density, data-transparent market with 300+ active dispensary locations; for Social Equity applicants navigating the priority licensing pipeline; and for investors assessing whether the price compression cycle has further to run before the market stabilizes around $1.2–1.4B annual revenue.
Revenue growth is decelerating while unit volume grows. Operators and vendors who build around units-sold efficiency (not per-unit price) will outperform. Watch the PA Senate vote on adult-use legalization as the primary regional demand-side catalyst that could shift cross-border traffic patterns materially.
New Jersey hit its first $1B+ year in 2025, but the number that actually matters for the next 12 months is $6.80/gram — the new adult-use flower price benchmark. Everything downstream of that: wholesale margins, operator viability, vendor pricing power, and the pace of new entrant success — is being reset by that number. NJ is still a large, data-rich, high-density market with strong regulatory clarity. But it is now a mature-market game of efficiency and scale, not an early-market game of capturing growth.
Market Overview
New Jersey legalized adult-use cannabis via the CREAMM Act (signed February 22, 2021), with the first recreational dispensary sales beginning April 21, 2022 through existing Alternative Treatment Centers. The market has grown from $210M in adult-use sales in 2022 to a certified $1.118B in 2025 — a 5.3× increase in three years. Including medical sales of $46.2M, total 2025 cannabis revenue reached $1.164B, a new annual record and a 15.8% increase over 2024's $1.005B combined total.
Revenue growth is decelerating as the market matures. Adult-use sales grew +11.8% in 2025 vs. +~25% in 2024, while price per gram declined sharply. The CRC's use of Metrc seed-to-sale data provides New Jersey with one of the most transparent pricing datasets of any state regulator, showing adult-use flower at $6.80/gram in April 2026 — down 23.3% from $8.86/gram in April 2025. Volume is growing; revenue per gram is compressing.
The 2025 full-year figure of $1.164B was certified and presented at the NJ-CRC May 14, 2026 board meeting — making it the most current official number available. Q1–Q3 2025 was $860M per the NJ-CRC 2025 Year in Review (Feb 2026), implying Q4 2025 delivered approximately $304M — seasonally in line with Green Wednesday and end-of-year shopping patterns. The 2024 annual total ($1.005B including medical) was certified in early 2025. The 2022 and 2023 figures are from NJ-CRC official press releases.
State Demographics
New Jersey's 9.3M population is the 11th-largest in the US and among the most densely settled, with approximately 1,263 persons per square mile — making it ideal for high-revenue retail cannabis. The state's median household income of $103,556 (ACS 2024) is among the highest in the nation, supporting premium product pricing even as per-gram prices compress. NJ's racial and ethnic diversity closely mirrors the demographics targeted by its social equity framework.
NJ's high income, extreme density, and proximity to New York City create one of the highest per-capita cannabis spending potentials in the country. The state's large Hispanic and Black populations — 35%+ combined — are central to the CREAMM Act's social equity framework, which defines Impact Zones and Economically Disadvantaged Areas (55 zip codes where 17% of NJ residents live) as priority licensing categories.
Regulatory & Licensing
The NJ Cannabis Regulatory Commission (NJ-CRC) oversees all adult-use and medical cannabis licensing, enforcement, and reporting under the CREAMM Act. Applications are accepted on a rolling basis — no deadline — with Social Equity designated businesses reviewed first, followed by Impact Zone, diversely-owned, and standard applicants. A conditional license is a provisional award giving operators time to satisfy remaining requirements for a full annual license.
| Status | Count | Notes |
|---|---|---|
| Total applications received | 3,212 | Rolling basis, all classes |
| Applications approved by CRC | 2,521 | Conditional or annual license awarded |
| Operational (inspected & open) | 300+ (397 as of Dec 2025) | Doubled Aug→Dec 2025 (182 to 397) |
| 84% of awarded licenses not yet operational | ~2,100 | 16–24 month buildout timeline for cultivation |
| Active medical patients | 52,877 | As of end of 2025; down from prior years |
| Municipalities opted in (of 564) | 211+ | CRC tracking via Obedio platform (2025) |
| Class | License Type | Application Fee | Annual Fee |
|---|---|---|---|
| Class 1 | Cultivator | $2,500–$10,000 | $10,000–$20,000 |
| Class 2 | Manufacturer | $2,500 | $5,000–$15,000 |
| Class 3 | Wholesaler | $1,000 | $5,000 |
| Class 4 | Distributor | $1,000 | $5,000 |
| Class 5 | Retailer (Dispensary) | $2,500–$10,000 | $5,000–$20,000 |
| Class 6 | Delivery | $1,000 | $2,500 |
State Incentives & Support Programs
Social Equity applicants (residents of Economically Disadvantaged Areas or with prior cannabis convictions) are reviewed before all other applications, regardless of submission date. 16% of licensed businesses carry SEA designation; 41% qualify as Impact Zone businesses.
Cultivators pay $2.50/oz SEEF (2025–2026 rate). Over $8M collected through Q3 2025 (cumulative $6.14M by early 2025). Funds designated for social equity investments in education, economic development, and community services. First disbursement framework under public development via CRC hearings.
41% of NJ cannabis businesses qualify as Impact Zone businesses, with priority application processing. Impact Zones are municipalities disproportionately impacted by cannabis prohibition enforcement.
State-funded training with 10 curriculum levels now complete (milestone achieved 2025). 2,000+ students registered; 200+ certificates of completion; 50+ cannabis companies enrolled employees. Portal fully translated into Spanish as of 2025.
CREAMM Act requires automatic expungement of certain marijuana convictions. AG Directive 2021-1 instructed prosecutors to dismiss pending charges for eligible offenses. Expungements expand the eligible owner pool for Social Equity priority licensing.
Unveiled December 2025, rolling out Q1 2026. A new statewide framework measuring and publicly recognizing meaningful community impact by cannabis businesses — moving equity from intent to verified outcomes through a tiered recognition system.
NJ's rolling application process with no deadline means qualified applicants can apply at any time — and Social Equity applicants are reviewed first regardless of when they apply. The Social Equity Scorecard (Q1 2026 rollout) will create a new visibility mechanism for SEA-owned businesses. CannBus members receive a direct connection to NJ-CRC community outreach resources and introductions to attorneys specializing in CREAMM Act applications.
Supply Chain
New Jersey's wholesale market is in active price compression. Adult-use flower prices tracked by NJ-CRC via Metrc have declined from approximately $11/gram in mid-2023 to $6.80/gram in April 2026 — a 38%+ decline over 36 months. The NJ-CRC publishes monthly price-per-gram data directly from Metrc at public board meetings, providing one of the most transparent wholesale price datasets of any state regulator. This transparency also means price declines are highly visible to all market participants simultaneously.
The cultivation activation lag is the key structural issue: only 8% of awarded cultivator licenses are operational as of late 2025. As the remaining 92% of awarded cultivation licenses complete 16–24 month buildouts and come online over 2025–2027, wholesale supply will increase and price compression will likely continue before any equilibrium is reached.
| Period | Price/gram (AU) | Medical Price/gram | YoY Change (AU) |
|---|---|---|---|
| April 2025 | $8.86 | $9.83 | — |
| October 2025 | ~$7.80 | ~$7.50 | Modeled-Est. |
| April 2026 | $6.80 | $6.89 | −23.3% YoY (AU); −29.9% (med) |
The cultivation activation gap — 92% of awarded cultivator licenses not yet operational — represents the single largest pending supply-side event in NJ's market. Equipment vendors, HVAC specialists, lighting suppliers, and construction contractors targeting this buildout cohort can reach operators across a multi-year window, before those operators' first harvests reshape wholesale prices further downward.
Consumer Demand
New Jersey allows all standard adult-use product categories. Manufactured product unit sales grew 38.6% YoY (Oct 2024 → Oct 2025) while dollar sales grew only 19.9% — confirming that consumers are buying more cannabis at lower prices per unit. The Green Wednesday (day before Thanksgiving) and 4/20 holidays consistently produce the highest daily sales in NJ, with Green Wednesday 2024 producing a $6.0M single-day record. Medical product demand is declining sharply (-41.5% YoY) as patients migrate to adult-use channels.
- Volume up, revenue per unit down: Manufactured AU units +38.6% YoY vs. dollar sales +19.9% — price sensitivity is high
- Out-of-state visitors legal: Non-residents can purchase up to 1 oz flower (half the 2 oz resident limit)
- PA cross-border demand: Up to 60% of border dispensary customers estimated to be Pennsylvania residents
- Green Wednesday record: $6.0M single-day (Nov 2024); 4/20 at $5.8M — holiday peaks are reliable planning anchors
- Medical-to-adult-use migration: Medical enrollment down 45% YoY as adult-use coverage and pricing converge
Product category mix shares are Modeled-Estimated from NJ-CRC board meeting presentations and DankReports analysis. NJ-CRC does not publicly publish a category-level revenue breakdown in standard reports, though Metrc data captures product type; the above estimates are consistent with mid-Atlantic adult-use market patterns.
County-Wise Sales
As of May 2026, dispensaries operate in all 21 New Jersey counties. The NJ-CRC does not publish a county-level retail sales dollar breakdown in standard reporting. The table below reflects a modeled allocation based on licensed dispensary concentration, municipal opt-in rates, and population weights. Bergen, Essex, Middlesex, and Morris counties are the highest-volume markets by dispensary density and population. Border counties (Burlington, Camden, Cumberland, Salem, Sussex) draw significant cross-border PA and NY visitor traffic.
| County Group | Key Counties | Est. Dispensary Share | Est. Sales Share | Notes |
|---|---|---|---|---|
| Northern NJ — Metro Core | Bergen, Essex, Hudson, Passaic | ~28% | ~32% | Highest-income, highest-density; NYC commuter catchment |
| Central NJ | Middlesex, Monmouth, Somerset, Union | ~24% | ~26% | Major suburban market; Middlesex is anchor county |
| Southern NJ — Border | Burlington, Camden, Gloucester, Salem | ~20% | ~19% | Heavy PA cross-border traffic; lower income demographics |
| Shore & Central Coast | Ocean, Atlantic, Cape May | ~14% | ~12% | Seasonal tourism uplift; Atlantic City visitor segment |
| Northern Rural / Sussex | Morris, Sussex, Warren, Hunterdon | ~8% | ~7% | Lower dispensary density; NY border visitor segment |
| Southwest | Cumberland, Salem, Cape May | ~6% | ~4% | Lowest density; primarily local resident market |
NJ-CRC does not publish publicly available county-level dollar-sales figures. The allocations above are Modeled-Estimated and should not be used for precise financial planning. For actual county-level data, a OPRA (Open Public Records Act) request to NJ-CRC is the appropriate channel. CannBus will update this table when official county-level data becomes available.
Cost-to-Open Benchmarks
NJ-specific estimated build-out costs, equipment spend, and time-to-open benchmarks by license type, reflecting NJ's real estate and regulatory environment.
| License Type | Cost / sq ft | Typical Total | Avg Time | NJ-Specific Driver |
|---|---|---|---|---|
| Class 5 Retail Dispensary | $200–$350 | $500K–$1.5M | 5–9 mo | NJ real estate premium; security systems; CRC inspection |
| Class 1 Cultivator | $300–$600 | $2M–$8M | 16–24 mo | Site control difficulty; high construction costs; buildout attrition |
| Class 2 Manufacturer / Infuser | $175–$375 | $800K–$3.5M | 7–14 mo | Extraction equipment lead times; GMP buildout requirements |
| Class 4 Distributor / Transporter | N/A | $150K–$500K | 3–6 mo | Vehicle fleet, GPS tracking, CRC-compliant manifest systems |
| Class 6 Delivery | N/A | $75K–$200K | 2–4 mo | Route software, insurance; lowest barrier-to-entry license class |
With 84% of awarded NJ licenses not yet operational and cultivator conversion at only 8%, the Class 1 buildout pipeline represents multi-year demand for HVAC, grow-room construction, lighting, fertigation, and compliance infrastructure vendors. NJ's high real estate costs mean Class 5 retailers are also actively seeking build-out cost optimization.
Vendor Demand Signal
Top vendor categories by active demand from NJ operators, based on CannBus directory inquiry patterns.
| Category | Signal | Primary Audience | Driver |
|---|---|---|---|
| Cultivation facility build-out | High | Class 1 cultivators (8% active) | 92% of cultivators still building — multi-year pipeline |
| Security systems (CRC-compliant) | High | All 300+ dispensaries + new activations | CRC security compliance mandatory for annual license |
| POS & inventory management | High | Class 5 retailers (300+) | NJ-CRC Metrc integration required; real-time seed-to-sale |
| Packaging & compliant labeling | Medium | Manufacturers, cultivators | High unit volumes; NJ-CRC labeling standards |
| 280E / SEEF accounting advisory | Medium | All license classes | NJ decoupled from 280E (2023) but federal exposure persists; SEEF filing complexity |
| Delivery fleet & routing software | Medium | Class 6 delivery operators | Rolling application; municipalities can restrict businesses not delivery itself |
Financials & Tax
New Jersey's cannabis tax structure is relatively straightforward compared to states like Illinois — a 6.625% state sales tax on adult-use retail sales, a cultivator-level Social Equity Excise Fee (SEEF) of $2.50/oz (2025–2026), and optional municipal local transfer taxes of up to 2%. Medical cannabis is fully exempt from NJ state sales tax.
A critically important NJ-specific advantage: New Jersey decoupled its state tax code from federal IRC Section 280E in May 2023 (A-3946/S-340). All NJ cannabis licensees may fully deduct ordinary and necessary business expenses on their NJ Gross Income Tax or Corporation Business Tax return for tax years beginning January 1, 2023. The previous $15M revenue cap on deductibility was also removed. This significantly reduces NJ operators' effective state tax burden relative to states that remain 280E-coupled.
| Tax / Fee | Rate | Applies To | Notes |
|---|---|---|---|
| State Sales Tax (ROT) | 6.625% | Adult-use retail sales | Standard NJ sales tax rate |
| Social Equity Excise Fee (SEEF) | $2.50/oz | Class 1 cultivators — recreational cannabis | 2025 & 2026 rate; set annually by CRC; medical exempt |
| Municipal Local Transfer Tax | Up to 2% | Cannabis sales within opted-in municipalities | Optional; set by each municipality |
| Medical Cannabis Sales Tax | 0% | Medical cannabis sales | Fully exempt from NJ sales tax since July 1, 2022 |
| NJ 280E Decoupling (State) | Full deductions | All NJ licensees (effective tax years from Jan 1, 2023) | All ordinary business expenses deductible on NJ state return |
| Federal 280E | ~21%+ | All federally-illegal cannabis businesses | Still applies federally; no NJ workaround for federal return |
| Q1–Q3 2025 Tax Revenue | ~$49.5M | Statewide adult-use | NJ-CRC 2025 Year in Review |
| Cumulative SEEF collected (to Feb 2025) | $6.14M+ | Since 2022 launch | Earmarked for social equity investments; disbursement framework in development |
Governor Murphy's FY2026 budget proposed raising the SEEF from $2.50/oz to $15/oz — a 500% increase — and adding a new $30/oz SEEF on intoxicating hemp products. As of this report, the Legislature has not advanced this proposal. If enacted, this would significantly increase cultivation costs and likely accelerate wholesale price compression as cultivators seek to pass costs through to dispensaries. CannBus will track and report any SEEF rate changes in the next quarterly refresh.
Neighboring States — Regional Impact
New Jersey is now surrounded by adult-use states on all but one border. Pennsylvania — NJ's largest land-border neighbor and a state with an estimated 1.8B in medical cannabis sales annually — remains the single biggest demand-side catalyst in NJ's regional picture. Border dispensaries in Burlington, Camden, Salem, and Gloucester counties report up to 60% of customers identifying as Pennsylvania residents.
NY launched adult-use in 2021 but rollout was extremely slow due to litigation. The NY market is now scaling, creating a more competitive backdrop for NJ operators targeting the NYC metro consumer. NJ's proximity to NYC gives it a geographic advantage — NY dispensaries in Manhattan are not yet dense enough to capture all NYC-area demand, and many NY residents still cross into NJ.
The PA House passed HB 1200 (adult-use) in May 2025, but the Republican-led Senate has not advanced it as of Q2 2026. PA's medical market generated $1.8B in dispensary sales in 2025. Governor Shapiro's FY2026 budget explicitly cites NJ, NY, DE, MD, and OH as competitors capturing PA tax dollars — border NJ dispensaries report 40–60% of customers from Pennsylvania. PA adult-use legalization would materially shift NJ border-market demand.
Delaware launched adult-use cannabis sales in 2024 under legislation signed in 2023. Delaware's small market (pop. ~1M) means relatively limited competitive impact on NJ — DE consumers now have local access, reducing the number of DE residents driving to NJ border dispensaries in Salem/Cumberland counties.
Connecticut launched adult-use in January 2023. CT primarily competes with NY for northwest NJ consumers, rather than directly with NJ's core markets. Limited direct traffic impact on NJ given geographic separation.
Maryland launched adult-use in July 2023 and generated $1.45B in 2025 sales — comparable to NJ's trajectory. MD primarily serves its own market and doesn't draw significantly from NJ's consumer base, but both states compete for the same regional investment dollars and operator attention.
NJ sits in the most mature cannabis market corridor in the US — surrounded by adult-use states on every border except PA. This creates a highly competitive environment for NJ-based operators (they can no longer rely on being the only legal option within driving distance), but a strong tailwind from PA cross-border demand that will persist until — and likely intensify with — any PA Senate action on adult-use. The net regional dynamic in 2026 is: NJ operators compete harder with NY and DE for residents, but gain from PA cross-border volume. On balance, positive for border-county dispensaries; neutral-to-negative for interior NJ markets.
Workforce
New Jersey's cannabis industry is among the faster-growing job markets in the 2025 Leafly/Vangst cannabis employment landscape — Vangst's 2025 report specifically called out NJ as one of the "newer markets still seeing significant growth," alongside NY, OH, WV, MS, and VT. The NJ Cannabis Training Academy (NJ-CTA) completed its full 10-level curriculum in 2025 and has enrolled 2,000+ students, with 50+ companies using it for employee training. UFCW Local 360 union organizing continued expanding into NJ dispensaries in 2025 (second NJ Leaf location unionized), adding a labor relations dimension for multi-location retail operators.
| Sector | Estimated FTE | Trend |
|---|---|---|
| Retail / Dispensary | ~5,500 | ▲ Rapid growth with 300+ dispensary openings |
| Cultivation & Extraction | ~1,800 | ▲ Growing as cultivation buildouts complete |
| Distribution / Transportation | ~600 | → Stable |
| Manufacturing / Processing | ~700 | ▲ Growing with Class 2 license activations |
| Corporate / Compliance / Legal | ~900 | ▲ Growing with market complexity |
| Total (Estimated) | ~9,500 | ▲ Significant YoY growth (new market) |
NJ cannabis employment figures are not published by NJ Department of Labor as a distinct category. The estimates above are based on Vangst 2025 industry data, CannBus analysis of dispensary headcount norms (~20–30 FTE per location at 300+ dispensaries), and NJ-CTA enrollment. Treat as directionally correct estimates, not official labor statistics.
Social Equity
New Jersey's social equity outcomes in cannabis licensing — per the NJ-CRC 2025 Year in Review — exceed national diversity benchmarks by a significant margin. As of end of 2025: nearly 70% of licensed businesses are diversely owned, 41% qualify as Impact Zone businesses, 29% are microbusinesses, 16% are designated Social Equity businesses, and 12% are led by individuals with prior marijuana-related convictions. The NJ-CRC says these outcomes "continue to exceed national diversity benchmarks for the cannabis industry."
The Social Equity Excise Fee (SEEF) has generated over $6.14M cumulative since 2022 (rate increased to $2.50/oz for 2025). However, no SEEF funds have been disbursed to date — the CRC held three public hearings in February 2025 to solicit recommendations from the public on how the money should be appropriated, and the framework for disbursement remains under development. The December 2025 Social Equity Scorecard launch is designed to create a verifiable outcomes framework for the first time.
| Category | Share of Licensed Businesses |
|---|---|
| Diversely owned (total) | ~70% |
| Impact Zone businesses | 41% |
| Microbusinesses | 29% |
| Social Equity designated | 16% |
| Led by individuals with prior marijuana convictions | 12% |
| Cumulative SEEF collected (to Feb 2025) | $6.14M+ |
| SEEF disbursed | $0 (framework under development) |
The NJ-CRC unveiled the Social Equity Scorecard in December 2025 — a tiered public recognition system that moves equity measurement "from intent to outcomes through verified actions, documentation, and data." The Scorecard rollout in Q1 2026 will create new visibility for businesses meeting equity benchmarks. For vendors targeting impact-zone or diverse-owned operators, the Scorecard will provide a publicly searchable registry of verified equity businesses — a potential sourcing tool for B2B partnerships.
Illicit Market
New Jersey's illicit cannabis market is shrinking as the legal market matures and price compression reduces the premium of licensed-market prices over illicit alternatives. The rapid expansion to 300+ legal dispensaries across all 21 counties significantly reduces travel distance to legal access — historically a primary driver of illicit market persistence. However, with only 270 stores and approximately 20% consumer capture estimated by some analysts (DankReports, April 2026), substantial illicit market volume persists, particularly in Bergen and Essex counties where legacy operators have been established for decades.
The hemp-derived THC market represents a growing gray-zone competitive pressure — products with less than 0.3% delta-9 THC by dry weight are federally legal, widely available, and not subject to NJ-CRC licensing requirements. This creates a price-and-access competitive pressure point particularly for edibles and vape categories.
NJ does not publish a state-tracked illicit market seizure report equivalent to Illinois's annual cannabis report. The "20% capture" estimate is from DankReports analysis (April 2026) and should be treated as a directional indicator. As legal dispensary density increases across NJ's 211+ opted-in municipalities, consumer capture rates are expected to improve.
Market Signals & Data Confidence
Four signals driving the NJ market through the next refresh cycle, followed by a full data confidence table.
PA House passed HB 1200 in May 2025; Republican-led Senate has not advanced it. A PA Senate vote to legalize would be the single largest regional demand-side shift — border NJ dispensaries could see cross-border volumes drop significantly. Timeline highly uncertain.
Governor Murphy's FY2026 budget proposed a 500% SEEF increase. If enacted, this would materially increase cultivator costs and accelerate wholesale price compression as operators attempt to pass the fee through. Legislative status: not advanced as of Q2 2026.
With only 8% of awarded cultivator licenses operational, NJ's wholesale supply is set to grow substantially as the remaining buildout cohort completes. The pace of cultivator activation will determine how quickly flower prices reach a new floor.
$6.14M+ in SEEF funds remain undisbursed. The CRC's public hearing process is developing disbursement recommendations. First disbursements — when they occur — will be a major signal for community investment and equity-program credibility.
| Data Point | Source Type | As-of Date | Confidence | How We Use It |
|---|---|---|---|---|
| 2025 full-year certified sales ($1.164B) | NJ-CRC official board meeting presentation | May 14, 2026 | High | Headline stat, market overview, stat grid |
| Adult-use sales 2025 ($1.118B, +11.8%) | NJ-CRC May 14, 2026 board meeting | May 14, 2026 | High | Market overview trend, key takeaway |
| Medical sales 2025 ($46.2M, −45%) | NJ-CRC May 14, 2026 board meeting | May 14, 2026 | High | Medical program stat card and section |
| Operational dispensaries (300+, all 21 counties) | NJ-CRC, May 4, 2026 | May 4, 2026 | High | Regulatory section, stat grid |
| Applications approved (2,521 of 3,212) | NJ-CRC May 14, 2026 board meeting | May 4, 2026 | High | Regulatory section licensing table |
| Adult-use flower price ($6.80/g, Apr 2026) | NJ-CRC Metrc data, public board meetings | Apr 2026 | High | Stat grid, supply chain table, analyst note |
| Prior year flower price ($8.86/g, Apr 2025) | NJ-CRC Metrc data / DankReports | Apr 2025 | High | YoY price comparison in supply chain |
| Active medical patients (52,877) | NJ-CRC 2025 Year in Review | End of 2025 | High | Medical program context, stat grid |
| Q1–Q3 2025 tax revenue ($49.5M) | NJ-CRC 2025 Year in Review | Q3 2025 | High | Financials section, key takeaway |
| SEEF cumulative total ($6.14M+) | NJ-CRC SEEF public hearings data, Feb 2025 | Feb 2025 | High | Social equity and financials sections |
| Social equity outcomes (70% diverse, 41% IZ, etc.) | NJ-CRC 2025 Year in Review (official) | End of 2025 | High | Social equity section and key takeaway |
| NJ 280E decoupling (effective Jan 2023) | NJ Law A-3946/S-340 (May 2023) | May 2023 | High | Financials section 280E note |
| Demographics (population, income, race/ethnicity) | US Census ACS 2020–2024 5-year | 2024 ACS | High | Demographics section |
| Neighbor state legal status (NY, PA, DE, CT, MD) | MPP / state regulator sites / Cannabis Business Times | Jun 2026 | High | Neighboring states section |
| Q4 2025 operational license surge (182→397) | Cannabis Wise Guys — NJ CRC Q4 2025 quarterly report | Dec 2025 | High | Regulatory section, activation context |
| AU manufactured unit volume (+38.6% YoY) | DankReports / NJ-CRC Metrc data (Oct 2024–Oct 2025) | Oct 2025 | High | Consumer demand section |
| Product category mix (AU sales %) | Modeled from NJ-CRC board data + regional benchmarks | Jun 2026 | Medium | Consumer demand chart |
| County-level sales allocation | Modeled from dispensary concentration + population | Jun 2026 | Medium | County-Wise Sales table |
| Workforce estimates (~9,500 FTE) | Vangst 2025 / CannBus dispensary headcount modeling | 2025 | Medium | Workforce section table |
| Illicit market share (~20% legal capture) | DankReports analysis, Apr 2026 | Apr 2026 | Low | Illicit market qualitative context |
Scenario Outlook & Market Snapshot
| Scenario | Key Assumption | Market Impact | Operator Action |
|---|---|---|---|
| Conservative | PA Senate blocks adult-use; SEEF increases to $15/oz; cultivators flood market | NJ revenue plateaus ~$1.1–1.2B; border-county dispensaries lose PA traffic; flower prices fall below $6/g | Lock in PA cross-border traffic now; delay cultivation expansion; focus on operational efficiency |
| Base Case | PA Senate stalls; SEEF stays $2.50/oz; cultivator pipeline comes online gradually | NJ revenue grows to $1.25–1.4B; price compression continues but slows; unit volume up 15–20% | Build for unit volume; optimize POS/inventory; develop loyalty programs; watch PA closely |
| Accelerated | PA adult-use fails in 2026; federal rescheduling/280E relief; SEEF stays low | NJ revenue reaches $1.5–1.7B by 2027; cross-border demand peaks; operators expand aggressively | Invest in multiple locations; cultivator buildout now; premium brand positioning while PA is still medical-only |
This is a CannBus-built illustrative composite, not an official statistic or investment rating. NJ scores 7.6/10 — high on market depth (8.8) and regulatory transparency (8.2, the best of any state for publicly available Metrc pricing data), moderate on retail whitespace (5.5, with 300+ dispensaries market is becoming dense) and competitive pressure (5.8, PA cross-border demand helps but NY/DE competition is real). This does not constitute financial or investment advice.
Outlook & Next Steps
92% of awarded cultivator licenses are not operational. As these facilities complete 16–24 month buildouts through 2025–2027, equipment, HVAC, lighting, and compliance vendors have a concentrated opportunity to establish NJ market relationships before competition intensifies.
Border-county dispensaries (Burlington, Camden, Salem, Gloucester) capturing up to 60% PA-resident customers have a durable competitive advantage that will persist until the PA Senate acts — which may be 2026 or later. Investment in PA-border locations now has asymmetric upside risk: if PA legalizes, you're already positioned; if it doesn't, you're capturing high-margin cross-border volume.
NJ's rolling application with SEA priority review means applying sooner is always better. The SEEF disbursement framework — when finalized — will create direct capital access for qualified equity operators. Track CRC board meetings for disbursement framework announcements.
NJ-CRC publishes Metrc-sourced price-per-gram data at every monthly board meeting — one of the only states to do this publicly. The April 2026 data ($6.80/gram) is the latest; May and June 2026 prices will signal whether the compression is stabilizing or continuing.
With flower prices down 23.3% YoY and cultivator supply still building, NJ has not yet found its per-gram floor. Underwrite investments assuming $6.00–6.50/gram by Q4 2026, not a recovery to $8–9. Operators who are cash-flow positive at $6/gram will be the resilient ones; operators whose unit economics require $8+/gram are at structural risk.
What's Free vs. What's a CannBus Membership
Included in This Report
- 2025 certified sales data ($1.164B) — freshest available
- License pipeline and activation data (May 2026)
- Full tax structure including NJ 280E decoupling detail
- Social equity outcomes (70% diverse-owned, SEEF data)
- Neighboring state status and PA cross-border dynamics
- Market signals and 3-scenario outlook
- Data confidence table with source links for all figures
CannBus Membership Adds
- NJ-specific cost-to-open benchmarks by license class
- Vendor demand signal with category rankings and operator contacts
- Verified vendor shortlists: POS, security, HVAC, compliance
- Downloadable data appendix (CSV with all tracked metrics)
- Priority alerts: CRC monthly price releases, new license activations
- Side-by-side comparison with NY, PA, and DE markets
The Pennsylvania Senate's response to HB 1200 (adult-use passed the House in May 2025) and any development on Governor Murphy's proposed SEEF increase ($2.50→$15/oz) are the two highest-impact items to monitor before the September 13 refresh. CannBus will publish alerts on either development as they occur.
Sources & Methodology
This report is based on official NJ Cannabis Regulatory Commission publications, US Census Bureau data, and clearly labeled industry estimates. All "Official" figures derive from the sources listed below. "Modeled-Estimated" figures (county-level sales, product category mix, workforce, illicit market share) are analyst constructions, disclosed as such in the Data Source & Confidence Table. This report does not constitute legal, financial, tax, or investment advice. Verify time-sensitive figures directly with the NJ-CRC (nj.gov/cannabis) before making business decisions.
Primary Sources
- NJ Cannabis Regulatory Commission (NJ-CRC) — Primary regulatory authority; all license data, board meetings, and official reports
- NJ-CRC 2025 Year in Review — Social equity outcomes, medical program data, NJ-CTA enrollment (Feb 5, 2026)
- Cann.dev — NJ Cannabis Retail June 2026 Update — Certified 2025 full-year sales ($1.164B), dispensary count (300+, all 21 counties), flower price ($6.80/g), applications (2,521 of 3,212) — from NJ-CRC May 14, 2026 board meeting
- DankReports — New Jersey Cannabis: 270 Stores, 20% Capture, $8.09 Flower — Market analysis, unit volume data, price compression narrative (Apr 17, 2026)
- Cannabis Wise Guys — NJ Market Insights — License activation surge (182→397, Q4 2025), cultivator conversion rates (8%), buildout context (Apr 2026)
- NJ-CRC — NJ Cannabis Sales Surpass $1 Billion in 2024 — 2024 annual sales certification ($1.005B); Social Equity Excise Fee cumulative (Dec 23, 2024)
- NJ Division of Taxation — SEEF Rate — Official SEEF rate ($2.50/oz for 2025 and 2026)
- TC Advisors CPA — NJ Cannabis Business Tax Guide 2026 — 280E decoupling detail, SEEF filing requirements (May 2026)
- Cannabis Business Times — NJ Governor Proposes 500% SEEF Increase — SEEF rate proposal to $15/oz; SEEF undisbursed background (Mar 5, 2025)
- Cannabis Business Times — States That Could Legalize in 2026 — PA legislative status, PA medical sales $1.8B, border dispensary cross-state customer data (Mar 20, 2026)
- U.S. Census Bureau QuickFacts — New Jersey — Population, income, density, demographics (Jul 2025 est.)